{"entity":{"id":"aurelien-marabelle","kind":"person","name":"Aurélien Marabelle","aka":[],"tldr":"Aurélien Marabelle is the immunotherapy investigator behind the tumour-agnostic pembrolizumab data in MSI-high cancers.","summary":"Aurélien Marabelle is Clinical Director of the Cancer Immunotherapy Program (DITEP) at Gustave Roussy. His specialisms are immuno-oncology, early-phase immunotherapy, MSI-high tumours and intratumoural therapy, with a focus on PD-1 and immune checkpoint inhibitors. He was lead author of the KEYNOTE-158 analysis in the Journal of Clinical Oncology, which reported the efficacy of pembrolizumab in non-colorectal cancers with high microsatellite instability or mismatch repair deficiency and supported the drug's tumour-agnostic approvals. He now leads early-phase immunotherapy trials at DITEP and works on delivering immunotherapy directly into tumours. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Marabelle%20A%5BAuthor%5D%20pembrolizumab"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1"],"drugs":["pembrolizumab"],"companies":[],"institutions":["gustave-roussy"],"pathways":[],"terms":["msi","tmb"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Clinical Director, Cancer Immunotherapy Program (DITEP), Gustave Roussy","institutionId":"gustave-roussy","specialisms":["Immuno-oncology","Early-phase immunotherapy","MSI-high tumours","Intratumoural therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Marabelle%20A%5BAuthor%5D%20pembrolizumab"}],"papers":[{"title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer (KEYNOTE-158)","journal":"JCO","year":2020,"doi":"10.1200/JCO.19.02105"}],"orcid":"0000-0002-5816-3019"},"route":"/people/aurelien-marabelle/","neighbours":{"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"institution":[{"id":"gustave-roussy","kind":"institution","name":"Gustave Roussy","route":"/institutions/gustave-roussy/"}],"term":[{"id":"msi","kind":"term","name":"Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR)","route":"/terms/msi/"},{"id":"tmb","kind":"term","name":"Tumour mutational burden (TMB)","route":"/terms/tmb/"}],"idea":[{"id":"idea-bio2-steroid-sparing-irae","kind":"idea","name":"Treat immunotherapy side-effects without wiping out the response","route":"/ideas/idea-bio2-steroid-sparing-irae/"}],"paper":[{"id":"paper-keynote-158-pembrolizumab-msi-high-noncolorectal-jco-2020","kind":"paper","name":"KEYNOTE-158: pembrolizumab in non-colorectal high microsatellite instability or mismatch repair-deficient cancer","route":"/key-papers/paper-keynote-158-pembrolizumab-msi-high-noncolorectal-jco-2020/"}]}}